Recent advances in CAR-based solid tumor immunotherapy
MH Shin, E Oh, Y Kim, DH Nam, SY Jeon, JH Yu… - Cells, 2023 - mdpi.com
Adoptive cell therapy using chimeric antigen receptor (CAR) technology is one of the most
advanced engineering platforms for cancer immunotherapy. CAR-T cells have shown …
advanced engineering platforms for cancer immunotherapy. CAR-T cells have shown …
CAR-T cell therapy for breast cancer: Current status and future perspective
Within the expanding therapeutic landscape for breast cancer (BC), metastatic breast cancer
(MBC) remains virtually incurable and tend to develop resistance to conventional treatments …
(MBC) remains virtually incurable and tend to develop resistance to conventional treatments …
Current Treatment Options for Renal Cell Carcinoma: Focus on Cell-Based Immunotherapy
A Hwang, V Mehra, J Chhetri, S Ali, M Tran, C Roddie - Cancers, 2024 - mdpi.com
Simple Summary Renal cell carcinoma (RCC) is common, affecting over 400,000 patients
globally each year. In limited stage disease and where surgery is a feasible therapeutic …
globally each year. In limited stage disease and where surgery is a feasible therapeutic …
Development of a multiscale mechanistic modeling framework integrating differential cellular kinetics of CAR T‐cell subsets and immunophenotypes in cancer patients
AM Salem, GM Mugundu… - CPT: Pharmacometrics & …, 2023 - Wiley Online Library
Chimeric antigen receptor (CAR) T‐cell subsets and immunophenotypic composition of the
pre‐infusion product, as well as their longitudinal changes following infusion, are expected …
pre‐infusion product, as well as their longitudinal changes following infusion, are expected …